BRIEF published on 03/20/2024 at 14:05, 8 months 14 days ago Celanese and Secarna Pharmaceuticals Announce Collaboration on Antisense Therapy Development Celanese Secarna Pharmaceuticals Antisense Oligonucleotides Drug Delivery Research Collaboration
PRESS RELEASE published on 03/20/2024 at 14:00, 8 months 14 days ago Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies Celanese and Secarna Pharmaceuticals collaborate on long-acting antisense therapy implants utilizing ASOs to target specific diseases for improved patient outcomes Celanese Secarna Pharmaceuticals Drug Delivery Antisense Therapy ASOs
PRESS RELEASE published on 11/03/2023 at 18:05, 1 year 1 month ago Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1
PRESS RELEASE published on 10/25/2023 at 15:00, 1 year 1 month ago Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs
PRESS RELEASE published on 10/17/2023 at 14:00, 1 year 1 month ago Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society
PRESS RELEASE published on 07/06/2023 at 14:00, 1 year 4 months ago Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases
PRESS RELEASE published on 06/05/2023 at 14:00, 1 year 5 months ago Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi
PRESS RELEASE published on 03/27/2023 at 16:04, 1 year 8 months ago Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases
Published on 12/03/2024 at 18:00, 23 minutes ago RE Royalties Provides $6.3 Million Financing for a 200 Megawatt Solar Project in Alberta, Canada
Published on 12/03/2024 at 17:45, 38 minutes ago CannapharmaRX Updates on Alberta Facility Progress and International Export Strategy
Published on 12/03/2024 at 16:36, 1 hour 47 minutes ago Coast2Coast First Aid and Aquatics Celebrates 10 Years Anniversary with 100 Free CPR Training for Marginalized Communities
Published on 12/03/2024 at 16:00, 2 hours 23 minutes ago Ascend Aesthetic Partners Marks First Year Uniting Top Surgeons in Aesthetic Care Nationwide
Published on 12/03/2024 at 15:45, 2 hours 38 minutes ago MacDonald Mines Announces Letter of Intent with Canuc Resources Corporation
Published on 12/03/2024 at 17:45, 38 minutes ago Kudelski IoT and PUFsecurity Combine IoT Security Strengths to Meet the Challenges of Increasing Global Regulation
Published on 12/03/2024 at 16:41, 1 hour 41 minutes ago TAKKT AG: Andreas Weishaar appointed as Chief Executive Officer of TAKKT AG
Published on 12/03/2024 at 16:09, 2 hours 13 minutes ago DWK Deutsche Wasserkraft AG launches cash capital increase with subscription rights offer
Published on 12/03/2024 at 15:50, 2 hours 32 minutes ago ANNOUNCEMENT OF INVITATION TO VOLUNTARY TENDER OFFER TO THE HOLDERS OF HOME REIT PLC ORD GBP0.01 ISSUED BY HOME REIT PLC – ISIN GB00BJP5HK17
Published on 12/03/2024 at 18:00, 23 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 12/03/2024 at 15:00, 3 hours 23 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
